One In Ten
1 in 10 people will experience problems with their liver at some point in their life.
Help us FIGHT liver disease.
I am Head of the Viral Hepatitis and Alcohol Research Group and Chief Scientific Officer of the Institute of Hepatology, London.
My research interests have largely focused on viral hepatitis, with special emphasis on the mechanisms of host immune control of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and the pathogenesis of liver damage triggered by these viruses. More recently I have expanded my areas of work to include new studies into Alcoholic Liver Disease (ALD) and susceptibilty to infection, and immunotherapeutic targets for hepatocellular carcinoma (HCC).
Publications and presentations (selected):
Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol.2010.184(1):287-295
Evans, A., Riva A., H. Cooksley, S. Phillips, S. Puranik, A. Nathwani, S. Brett, Naoumov NV, Chokshi S 2008. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology.2008 Sep;48(3):759-69.
Chokshi S, Cooksley H*, Maayan Y, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Frederick D, Neumann A, Brosgart CL, Naoumov NV. 2008. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob. Agents Chemother. 52:312-320.
Palma E, Clemens D, Riva A, Williams R, Chokshi S. Perturbation of the mitochondrial network architecture in an in vitro model of alcohol-induced liver toxicity. Oral presentation AASLD monothematic conference. Atlanta, Georgia, USA, 2012.
The Foundation runs on donations. Every little helps us continue our work.